3016431
print

B-Cell CD20 Expression by Flow Cytometry, Quantitative

CD20 QUANT
Example Reports
Negative
Positive

Ordering Recommendation

Use to enumerate B cells in peripheral blood or monitor response to rituximab therapy in patients with autoimmune disorders. To evaluate for primary B-cell deficiency (eg, agammaglobulinemia, common variable immunodeficiency [CVID], hypogammaglobulinemia), order B Cell Subset Analysis (3002216).

New York DOH Approval Status

This test is New York state approved.

Specimen Required

Patient Preparation
Collect

Green (sodium heparin). Also acceptable: lavender (EDTA) or pink (K2EDTA).

Specimen Preparation

Transport 5 mL whole blood. (Min: 1 mL). Do not freeze.

Storage/Transport Temperature

Preferred transport temp: Room temperature. Also acceptable: Refrigerated. Specimen should be received within 72 hours ofcollection for optimal viable testing.

Unacceptable Conditions

Clotted, hemolyzed, or frozen specimens. Specimens received more than 72 hours from collection.

Remarks

Clinical history, differential diagnosis, and any relevant pathology reports.

Stability

Ambient: 72 hours; Refrigerated: 72 hours; Frozen: Unacceptable.

Methodology

Flow Cytometry

Performed

Sun-Sat

Reported

1-2 days

Reference Interval

Refer to report.

Interpretive Data



Compliance Category

Laboratory Developed Test (LDT)

Note

Monoclonal antibody-based therapies, such as rituximab that target the CD20 antigen, are being used to treat patients with avariety of autoimmune disorders. The effectiveness of this therapy is dependent on the degree of B-cell suppression andvaries by disease state. This assay is designed to detect low levels of B cells and provide quantitative cell numbers in thesetting of rituximab-treated patients using both CD20 and CD19.

Hotline History

View Hotline History

 

Hotline History

Date of Change
Test Name Change
Methodology
Performance/Reported Schedule
Specimen Requirements
Reference Interval
Interpretive Data
Note
CPT Code
Component Change
Other Interface Change
New Test
Inactive
04/02/2024
X
N/A

CPT Codes

86355; 86356

Are you an ARUP Client? Click here for your pricing.

Components

Component Test Code* Component Chart Name LOINC
3016432 CD19+ Percent of Lymphocytes 8117-4
3016433 CD19+ Count of Lymphocytes 8116-6
3016434 CD20+ Percent of CD19+ Cells 94689-7
3016435 CD20+ Count of CD19+ Cells 9558-8
3016436 Cell Viability 33193-4
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.

Aliases

  • B cell depletion
  • CD19
  • CD20 on B Cells
  • high sensitivity B cell count
  • Kesimpta monitoring
  • Obinutuzumab
  • Ocrelizumab
  • Ocrevus monitoring
  • Ofatumumab
  • Rituxan monitoring
  • Rituximab
  • Veltuzumab
B-Cell CD20 Expression by Flow Cytometry, Quantitative